CD44 and ovarian cancer: Furthermore, a study by Chen et al. demonstrated that miR-200c was significantly downregulated in the more aggressive and chemoresistant phenotype CD117+/CD44+ ovarian cancer stem cells compared with the CD117−/CD44− cells.